Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Pituitary Neoplasms 16Neuroendocrine Tumors 15Multiple Endocrine Neoplasia Type 1 9Inflammation 4Acromegaly 4Sexual Dysfunction, Physiological 3Pheochromocytoma 3Obesity 3Neoplasms 3Gastro-enteropancreatic neuroendocrine tumor 3Thyroid Cancer, Papillary 2Prostatic Neoplasms 2Pituitary Diseases 2Paraganglioma 2Pain, Postoperative 2Carcinoid Tumor 2Adrenal Gland Neoplasms 2Zollinger-Ellison Syndrome 1Vitamin D Deficiency 1Serotonin Syndrome 1Pituitary ACTH Hypersecretion 1Pancreatic Neuroendocrine Tumors 1Pancreatic Neoplasms 1Pain 1Neuroendocrine Tumour With Carcinoid Symptoms 1Multiple Endocrine Neoplasia 1Meningioma 1Melanoma 1Medulloblastoma 1Lung Neoplasms 1

Interventions

candesartan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Essential Hypertension × Endocrine × Clear all
NCT01629225 2014-11-18

GRK4 Polymorphisms Blood Pressure Response to Candesartan

Third Military Medical University

Phase 4 Unknown
500 enrolled
Endocrine

Essential Hypertension, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡